Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 8/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | DNM2 | P50570 | 9/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13597454 | 0.88 | KMT2A (0.55) | SLC29A1KMT2ADNM2 | |
| SCHEMBL7776204 | 0.84 | SLC29A1 (0.50) | SLC29A1KMT2ADNM2KCNH3 | |
| SCHEMBL7774646 | 0.84 | SLC29A1 (0.50) | SLC29A1KMT2ADNM2KCNH3 | |
| SCHEMBL13295563 | 0.83 | SLC29A1 (0.66) | SLC29A1KMT2A | |
| SCHEMBL6720244 | 0.82 | SLC29A1 (0.51) | SLC29A1KMT2ADNM2KCNH3 | |
| SCHEMBL14715387 | 0.81 | SLC29A1 (0.60) | SLC29A1KMT2A | |
| SCHEMBL2844587 | 0.81 | SLC29A1 (0.57) | SLC29A1KMT2A | |
| SCHEMBL2219150 | 0.81 | SLC29A1 (0.49) | SLC29A1KMT2A | |
| SCHEMBL6716597 | 0.80 | SLC29A1 (0.50) | SLC29A1KMT2ADNM2KCNH3 | |
| SCHEMBL1691726 | 0.80 | SLC29A1 (0.51) | SLC29A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | SLC29A1 2776/4885KMT2A 411/4885DNM2 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.